Bicycle Therapeutics plc Increase (Decrease) in Deferred Revenue
Bicycle Therapeutics plc (BCYC) reported Increase (Decrease) in Deferred Revenue of -$950.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-07-30
- Bicycle Therapeutics plc increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was -$244.00K.
- Bicycle Therapeutics plc increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$706.00K.
- Bicycle Therapeutics plc increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$47.34M.
- Bicycle Therapeutics plc increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$9.40M.
- Bicycle Therapeutics plc increase (decrease) in deferred revenue for fiscal 2025 was -$69.19M.
- Bicycle Therapeutics plc increase (decrease) in deferred revenue for fiscal 2024 was -$31.95M, a 146.34% decline from fiscal 2023.
- Bicycle Therapeutics plc increase (decrease) in deferred revenue for fiscal 2023 was $68.95M.
- Bicycle Therapeutics plc increase (decrease) in deferred revenue for fiscal 2022 was -$2.13M, a 105.75% decline from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$244.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$950.00K 10-Q · filed 2026-07-30 | -$48.29M derived: sum of 3 quarters · filed 2026-07-30 | -$57.69M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$706.00K 10-Q · filed 2026-04-30 | -$48.05M derived: sum of 2 quarters · filed 2026-04-30 | -$57.44M derived: sum of 3 quarters · filed 2026-04-30 | -$60.17M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$47.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$56.74M derived: sum of 2 quarters · filed 2026-03-17 | -$59.46M derived: sum of 3 quarters · filed 2026-07-30 | -$69.19M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$9.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$12.12M derived: sum of 2 quarters · filed 2026-07-30 | -$21.85M 10-Q · filed 2025-10-30 | -$22.53M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$12.45M 10-Q · filed 2026-07-30 | -$13.13M derived: sum of 3 quarters · filed 2026-07-30 | -$15.73M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$9.73M 10-Q · filed 2026-04-30 | -$10.40M derived: sum of 2 quarters · filed 2026-04-30 | -$13.01M derived: sum of 3 quarters · filed 2026-04-30 | -$22.12M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$3.28M derived: sum of 2 quarters · filed 2026-03-17 | -$12.40M derived: sum of 3 quarters · filed 2026-03-17 | -$31.95M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$11.72M derived: sum of 2 quarters · filed 2025-10-30 | -$31.27M 10-Q · filed 2025-10-30 | -$36.56M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | -$9.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$28.67M 10-Q · filed 2025-08-08 | -$33.96M derived: sum of 3 quarters · filed 2026-03-17 | $55.73M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$19.55M 10-Q · filed 2025-05-01 | -$24.84M derived: sum of 2 quarters · filed 2026-03-17 | $64.85M derived: sum of 3 quarters · filed 2026-03-17 | $54.30M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $84.41M derived: sum of 2 quarters · filed 2026-03-17 | $73.85M derived: sum of 3 quarters · filed 2026-03-17 | $68.95M 10-K · filed 2026-03-17 |
| 2023-09-30 | $89.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $79.14M derived: sum of 2 quarters · filed 2024-10-31 | $74.24M 10-Q · filed 2024-10-31 | $73.07M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$10.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$15.45M 10-Q · filed 2024-08-06 | -$16.62M derived: sum of 3 quarters · filed 2025-02-25 | -$19.66M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$4.90M 10-Q · filed 2024-05-02 | -$6.07M derived: sum of 2 quarters · filed 2025-02-25 | -$9.11M derived: sum of 3 quarters · filed 2025-02-25 | -$3.19M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$4.21M derived: sum of 2 quarters · filed 2025-02-25 | $1.72M derived: sum of 3 quarters · filed 2025-02-25 | -$2.13M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.88M derived: sum of 2 quarters · filed 2023-11-02 | -$969.00K 10-Q · filed 2023-11-02 | $7.67M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $5.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.07M 10-Q · filed 2023-08-03 | $10.72M derived: sum of 3 quarters · filed 2024-02-20 | $40.74M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$3.85M 10-Q · filed 2023-05-04 | $4.79M derived: sum of 2 quarters · filed 2024-02-20 | $34.82M derived: sum of 3 quarters · filed 2024-02-20 | $33.03M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $8.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $38.67M derived: sum of 2 quarters · filed 2024-02-20 | $36.88M derived: sum of 3 quarters · filed 2024-02-20 | $37.12M 10-K · filed 2024-02-20 |
| 2021-09-30 | $30.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $28.24M derived: sum of 2 quarters · filed 2022-11-03 | $28.47M 10-Q · filed 2022-11-03 | $25.31M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.55M 10-Q · filed 2022-08-04 | -$4.71M derived: sum of 3 quarters · filed 2023-02-28 | -$5.94M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $236.00K 10-Q · filed 2022-05-05 | -$2.92M derived: sum of 2 quarters · filed 2023-02-28 | -$4.16M derived: sum of 3 quarters · filed 2023-02-28 | -$5.25M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$4.39M derived: sum of 2 quarters · filed 2023-02-28 | -$5.48M derived: sum of 3 quarters · filed 2023-02-28 | $24.62M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$2.32M derived: sum of 2 quarters · filed 2021-11-04 | $27.78M 10-Q · filed 2021-11-04 | $22.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $29.01M 10-Q · filed 2021-08-05 | $24.22M derived: sum of 3 quarters · filed 2022-03-01 | $24.05M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $30.10M 10-Q · filed 2021-05-06 | $25.31M derived: sum of 2 quarters · filed 2022-03-01 | $25.14M derived: sum of 3 quarters · filed 2022-03-01 | $26.14M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$4.97M derived: sum of 2 quarters · filed 2022-03-01 | -$3.97M derived: sum of 3 quarters · filed 2022-03-01 | -$9.29M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $825.00K derived: sum of 2 quarters · filed 2020-11-05 | -$4.50M 10-Q · filed 2020-11-05 | -$5.19M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $998.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$4.33M 10-Q · filed 2020-08-05 | -$5.02M derived: sum of 3 quarters · filed 2021-03-11 | -$6.07M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | -$5.33M 10-Q · filed 2020-05-07 | -$6.02M derived: sum of 2 quarters · filed 2021-03-11 | -$7.06M derived: sum of 3 quarters · filed 2021-03-11 | |
| 2018-12-31 | -$689.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$1.74M derived: sum of 2 quarters · filed 2021-03-11 | -$3.95M 10-K · filed 2021-03-11 | |
| 2018-09-30 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$3.26M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | -$2.21M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $14.08M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |